Agenus Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Agenushan disminuido a un ritmo medio anual de -9.4%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 13.5%.

Información clave

-12.5%

Tasa de crecimiento de los beneficios

14.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	9.9%
Rentabilidad financiera	n/a
Margen neto	-157.4%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

FDA accepts Agenus' balstilimab BLA under "priority review" status

Jun 17

Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy

May 26

Agenus shares fall after Q1 topline miss

May 06

Is Agenus Inc. (NASDAQ:AGEN) Popular Amongst Institutions?

Feb 15

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Agenus. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:AGEN Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	156	-246	79
30 Sep 23	101	-271	83
30 Jun 23	99	-263	82
31 Mar 23	95	-240	80
31 Dec 22	98	-220	81
30 Sep 22	90	-215	78
30 Jun 22	320	18	81
31 Mar 22	310	-19	79
31 Dec 21	296	-24	76
30 Sep 21	307	4	74
30 Jun 21	69	-226	67
31 Mar 21	85	-190	65
31 Dec 20	88	-181	59
30 Sep 20	91	-174	52
30 Jun 20	97	-168	49
31 Mar 20	85	-171	46
31 Dec 19	150	-108	46
30 Sep 19	122	-126	43
30 Jun 19	115	-113	41
31 Mar 19	115	-87	39
31 Dec 18	37	-160	37
30 Sep 18	39	-147	37
30 Jun 18	29	-151	36
31 Mar 18	18	-158	35
31 Dec 17	43	-121	34
30 Sep 17	40	-112	33
30 Jun 17	41	-116	33
31 Mar 17	44	-113	32
31 Dec 16	23	-127	33
30 Sep 16	25	-117	33
30 Jun 16	27	-89	31
31 Mar 16	27	-101	32
31 Dec 15	25	-88	28
30 Sep 15	19	-98	25
30 Jun 15	14	-93	23
31 Mar 15	10	-61	22
31 Dec 14	7	-43	21
30 Sep 14	6	-22	20
30 Jun 14	5	-22	18
31 Mar 14	3	-25	17
31 Dec 13	3	-33	14
30 Sep 13	4	-33	14
30 Jun 13	4	-32	13

Ingresos de calidad: AGEN actualmente no es rentable.

Margen de beneficios creciente: AGEN actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: AGEN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 9.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de AGEN en el último año con su media de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: AGEN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).

Rentabilidad financiera

Alta ROE: AGENEl pasivo de la empresa supera su activo, por lo que es difícil calcular su Rentabilidad de los fondos propios.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Agenus Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Recent updates

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul

Investor sentiment deteriorated over the past week

Agenus: It's Always Tomorrow

Agenus Initiates Botensilimab Phase 2 Activate Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus GAAP EPS of -$0.17, revenue of $20.93M

Agenus Inc. Announces First Patient Dosed in Phase 1 Study of AGEN1571 (Anti-ILT2) in Advanced Solid Tumors

Agenus Inc. to Report Q2, 2022 Results on Aug 09, 2022

Agenus: Successfully Pulled Itself Away From Disaster

Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI Congress

Agenus Inc. Announces Positive Headline Results from A Pre-Specified Efficacy Interim Analysis of the Aresvi 006 Phase III Trial Evaluating Their Investigational RSV Vaccine in Adults Aged 60 Years and Above

Price target decreased to US$7.50

Consensus estimates of losses per share improve by 21%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Agenus Inc., Annual General Meeting, Jun 08, 2022

Insufficient new directors

Agenus: Not Quite Enough

Agenus Inc. Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance

Consensus revenue estimates fall by 10%

Auditors Have Doubts About Agenus (NASDAQ:AGEN)

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Inc. to Report Q4, 2021 Results on Mar 01, 2022

Agenus: Making Another Effort With The FDA

Chief Medical Officer exercised options and sold US$118k worth of stock

Insufficient new directors

Agenus Inc. Announces Publication of Results in the Journal of Clinical Oncology from a Global Phase 2 Clinical Study of Balstilimab (Bal) Plus Zalifrelimab

Insufficient new directors

Third quarter 2021 earnings released: EPS US$0.76 (vs US$0.28 loss in 3Q 2020)

Forecast to breakeven in 2021

Desglose de ingresos y gastos
Beta